Personalized Intervention Strategy Based on a Risk Score Generated From Subcutaneous Insertable Cardiac Monitor: Results From Phase 1 of ALLEVIATE‐HF

Background Diagnostic variables from insertable cardiac monitors may be useful in identifying patients at increased risk of heart failure (HF) events. High‐risk alerts must be coupled with interventions to improve outcomes. We aim to assess the safety of a predefined protocolized intervention pathwa...

Full description

Saved in:
Bibliographic Details
Main Authors: Rami Kahwash, Michael R. Zile, Prasad Chalasani, Barry Bertolet, Laura Gravelin, Muhammad Shahzeb Khan, Jennifer Wehking, Brian Van Dorn, Shantanu Sarkar, Verla Laager, Bart Gerritse, Aimee Laechelt, Javed Butler
Format: Article
Language:English
Published: Wiley 2024-10-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.124.035501
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850284007835566080
author Rami Kahwash
Michael R. Zile
Prasad Chalasani
Barry Bertolet
Laura Gravelin
Muhammad Shahzeb Khan
Jennifer Wehking
Brian Van Dorn
Shantanu Sarkar
Verla Laager
Bart Gerritse
Aimee Laechelt
Javed Butler
author_facet Rami Kahwash
Michael R. Zile
Prasad Chalasani
Barry Bertolet
Laura Gravelin
Muhammad Shahzeb Khan
Jennifer Wehking
Brian Van Dorn
Shantanu Sarkar
Verla Laager
Bart Gerritse
Aimee Laechelt
Javed Butler
author_sort Rami Kahwash
collection DOAJ
description Background Diagnostic variables from insertable cardiac monitors may be useful in identifying patients at increased risk of heart failure (HF) events. High‐risk alerts must be coupled with interventions to improve outcomes. We aim to assess the safety of a predefined protocolized intervention pathway activated by insertable cardiac monitor high‐risk alerts. Methods and Results ALLEVIATE‐HF (Algorithm Using LINQ Sensors for Evaluation and Treatment of Heart Failure) Phase 1 was a randomized interventional study enrolling patients with New York Heart Association class II/III and a recent HF event. A HF risk score based on insertable cardiac monitor diagnostics, including impedance, respiration rate, atrial fibrillation burden, heart rate during atrial fibrillation, heart rate variability, and activity duration, was calculated. A protocolized intervention pathway was activated when high‐risk scores were detected that involved physician‐prescribed nurse‐implemented uptitration of diuretic for 4 days, unless safety rule‐out conditions were met. Interventions could be repeated if high‐risk scores persisted and did not require worsening symptoms. In total, 59 patients were randomized (mean age 68.2±11.8 years; 59.3% male); 67.8% with ejection fraction ≥50%. The mean follow‐up was 11.8±8.1 months. Overall, 146 high‐risk scores were recorded in 33 patients and 118 interventions occurred in 75 (51.4%) high‐risk alerts that did not meet safety rule‐out criteria. There were no serious adverse events and 13 adverse events related to interventions. In patients with symptoms at intervention initiation, symptoms resolved in 37 interventions (80%) and worsened in 8 (17%). In asymptomatic patients, symptoms developed in 3 interventions (7%). Conclusions A personalized medication intervention based on insertable cardiac monitor risk score can be safely instituted in patients with HF, irrespective of symptoms. Registration URL: https://www.clinicaltrials.gov; Unique Identifier: NCT04452149.
format Article
id doaj-art-6d06d9aaef18466ba5b5cc440685cb0f
institution OA Journals
issn 2047-9980
language English
publishDate 2024-10-01
publisher Wiley
record_format Article
series Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
spelling doaj-art-6d06d9aaef18466ba5b5cc440685cb0f2025-08-20T01:47:40ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802024-10-01132010.1161/JAHA.124.035501Personalized Intervention Strategy Based on a Risk Score Generated From Subcutaneous Insertable Cardiac Monitor: Results From Phase 1 of ALLEVIATE‐HFRami Kahwash0Michael R. Zile1Prasad Chalasani2Barry Bertolet3Laura Gravelin4Muhammad Shahzeb Khan5Jennifer Wehking6Brian Van Dorn7Shantanu Sarkar8Verla Laager9Bart Gerritse10Aimee Laechelt11Javed Butler12The Ohio State University Columbus OH USAMedical University of South Carolina Charleston SC USAFlorida Heart Center Fort Pierce FL USACardiology Associates Research LLC North Mississippi Medical Center Tupelo MS USAMount Carmel Health System Columbus OH USADuke University Medical Center Durham NC USAMedtronic Mounds View MN USAMedtronic Mounds View MN USAMedtronic Mounds View MN USAMedtronic Mounds View MN USAMedtronic Bakken Research Center Maastricht NetherlandsMedtronic Mounds View MN USABaylor Scott and White Research Institute Dallas TX USABackground Diagnostic variables from insertable cardiac monitors may be useful in identifying patients at increased risk of heart failure (HF) events. High‐risk alerts must be coupled with interventions to improve outcomes. We aim to assess the safety of a predefined protocolized intervention pathway activated by insertable cardiac monitor high‐risk alerts. Methods and Results ALLEVIATE‐HF (Algorithm Using LINQ Sensors for Evaluation and Treatment of Heart Failure) Phase 1 was a randomized interventional study enrolling patients with New York Heart Association class II/III and a recent HF event. A HF risk score based on insertable cardiac monitor diagnostics, including impedance, respiration rate, atrial fibrillation burden, heart rate during atrial fibrillation, heart rate variability, and activity duration, was calculated. A protocolized intervention pathway was activated when high‐risk scores were detected that involved physician‐prescribed nurse‐implemented uptitration of diuretic for 4 days, unless safety rule‐out conditions were met. Interventions could be repeated if high‐risk scores persisted and did not require worsening symptoms. In total, 59 patients were randomized (mean age 68.2±11.8 years; 59.3% male); 67.8% with ejection fraction ≥50%. The mean follow‐up was 11.8±8.1 months. Overall, 146 high‐risk scores were recorded in 33 patients and 118 interventions occurred in 75 (51.4%) high‐risk alerts that did not meet safety rule‐out criteria. There were no serious adverse events and 13 adverse events related to interventions. In patients with symptoms at intervention initiation, symptoms resolved in 37 interventions (80%) and worsened in 8 (17%). In asymptomatic patients, symptoms developed in 3 interventions (7%). Conclusions A personalized medication intervention based on insertable cardiac monitor risk score can be safely instituted in patients with HF, irrespective of symptoms. Registration URL: https://www.clinicaltrials.gov; Unique Identifier: NCT04452149.https://www.ahajournals.org/doi/10.1161/JAHA.124.035501heart failureprotocolized intervention pathwayremote monitoringrisk metric
spellingShingle Rami Kahwash
Michael R. Zile
Prasad Chalasani
Barry Bertolet
Laura Gravelin
Muhammad Shahzeb Khan
Jennifer Wehking
Brian Van Dorn
Shantanu Sarkar
Verla Laager
Bart Gerritse
Aimee Laechelt
Javed Butler
Personalized Intervention Strategy Based on a Risk Score Generated From Subcutaneous Insertable Cardiac Monitor: Results From Phase 1 of ALLEVIATE‐HF
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
heart failure
protocolized intervention pathway
remote monitoring
risk metric
title Personalized Intervention Strategy Based on a Risk Score Generated From Subcutaneous Insertable Cardiac Monitor: Results From Phase 1 of ALLEVIATE‐HF
title_full Personalized Intervention Strategy Based on a Risk Score Generated From Subcutaneous Insertable Cardiac Monitor: Results From Phase 1 of ALLEVIATE‐HF
title_fullStr Personalized Intervention Strategy Based on a Risk Score Generated From Subcutaneous Insertable Cardiac Monitor: Results From Phase 1 of ALLEVIATE‐HF
title_full_unstemmed Personalized Intervention Strategy Based on a Risk Score Generated From Subcutaneous Insertable Cardiac Monitor: Results From Phase 1 of ALLEVIATE‐HF
title_short Personalized Intervention Strategy Based on a Risk Score Generated From Subcutaneous Insertable Cardiac Monitor: Results From Phase 1 of ALLEVIATE‐HF
title_sort personalized intervention strategy based on a risk score generated from subcutaneous insertable cardiac monitor results from phase 1 of alleviate hf
topic heart failure
protocolized intervention pathway
remote monitoring
risk metric
url https://www.ahajournals.org/doi/10.1161/JAHA.124.035501
work_keys_str_mv AT ramikahwash personalizedinterventionstrategybasedonariskscoregeneratedfromsubcutaneousinsertablecardiacmonitorresultsfromphase1ofalleviatehf
AT michaelrzile personalizedinterventionstrategybasedonariskscoregeneratedfromsubcutaneousinsertablecardiacmonitorresultsfromphase1ofalleviatehf
AT prasadchalasani personalizedinterventionstrategybasedonariskscoregeneratedfromsubcutaneousinsertablecardiacmonitorresultsfromphase1ofalleviatehf
AT barrybertolet personalizedinterventionstrategybasedonariskscoregeneratedfromsubcutaneousinsertablecardiacmonitorresultsfromphase1ofalleviatehf
AT lauragravelin personalizedinterventionstrategybasedonariskscoregeneratedfromsubcutaneousinsertablecardiacmonitorresultsfromphase1ofalleviatehf
AT muhammadshahzebkhan personalizedinterventionstrategybasedonariskscoregeneratedfromsubcutaneousinsertablecardiacmonitorresultsfromphase1ofalleviatehf
AT jenniferwehking personalizedinterventionstrategybasedonariskscoregeneratedfromsubcutaneousinsertablecardiacmonitorresultsfromphase1ofalleviatehf
AT brianvandorn personalizedinterventionstrategybasedonariskscoregeneratedfromsubcutaneousinsertablecardiacmonitorresultsfromphase1ofalleviatehf
AT shantanusarkar personalizedinterventionstrategybasedonariskscoregeneratedfromsubcutaneousinsertablecardiacmonitorresultsfromphase1ofalleviatehf
AT verlalaager personalizedinterventionstrategybasedonariskscoregeneratedfromsubcutaneousinsertablecardiacmonitorresultsfromphase1ofalleviatehf
AT bartgerritse personalizedinterventionstrategybasedonariskscoregeneratedfromsubcutaneousinsertablecardiacmonitorresultsfromphase1ofalleviatehf
AT aimeelaechelt personalizedinterventionstrategybasedonariskscoregeneratedfromsubcutaneousinsertablecardiacmonitorresultsfromphase1ofalleviatehf
AT javedbutler personalizedinterventionstrategybasedonariskscoregeneratedfromsubcutaneousinsertablecardiacmonitorresultsfromphase1ofalleviatehf